Methylene Blue (MB), an FDA approved dye, has been widely used in clinical applications. However, issues remain for its use as contrast agent: production of 1O2, reduction into leuco-MB, and nonspecific tagging. These issues were addressed by loading MB into Poly-Lactic-co-Glycolic Acid (PLGA) particles.